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Summary
Niemann-Pick type D (NPD) disease is a progressive
neurodegenerative disorder characterized by the accu-
mulation of tissue cholesterol and sphingomyelin. This
disorder is relatively common in southwestern Nova
Scotia, because of a founder effect. Our previous studies,
using classic linkage analysis of this large extended kin-
dred, defined the critical gene region to a 13-cM chro-
mosome segment between D18S40 and D18S66. A re-
cently isolated gene from this region, NPC1, is mutated
in the majority of patients with Niemann-Pick type C
disease. We have identified a point mutation within this
gene (G3097rT; Gly992rTrp) that shows complete linkage
disequilibrium with NPD, confirming that NPD is an
allelic variant of NPC1.
Introduction
Niemann-Pick (NP) type II disease is an autosomal re-
cessive lysosomal storage disease characterized by an ac-
cumulation of tissue cholesterol and sphingomyelin con-
sequent to abnormal intracellular translocation of
LDL-derived cholesterol (Spence and Callahan 1989;
Pentchev et al. 1995). Affected children suffer a pro-
gressive and severe degeneration of the nervous system
and usually die within the first 2 decades of life.
NP type II has been subclassified as type C (NPC)
(MIM 257220) and type D (NPD) (MIM 257250). NPD
has been reported only in descendants of an Acadian
couple who married in ∼1700 in what today is Nova
Scotia (Winsor and Welch 1978). In contrast, NPC is
clinically heterogeneous and has been identified in many
ethnic populations. Recent reports have identified two
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complementation groups within NPC (Steinberg et al.
1994; Vanier et al. 1996). The genetic defect of themajor
complementation group (representing 27 of 32 patients)
has been localized to chromosome 18q11-12 (Carstea
et al. 1993), and the gene mutated in these patients,
NPC1, has been isolated and has been identified as hav-
ing a critical role in the regulation of intracellular cho-
lesterol trafficking (Carstea et al. 1997). Linkage analysis
of NPD mapped this mutation to the same region of
chromosome 18 as that containing NPC1, suggesting
that these two disorders are likely to be allelic variants
(Greer et al. 1997). We here report mutation analysis of
NPC1 in our population, which confirms that this gene
is also mutated in NPD disease.
Subjects and Methods
Subjects
Peripheral blood, fibroblast cell lines, and/or paraffin-
embedded tissue was collected, with ethical approval
from the IWKGrace Health Centre (Halifax), from1150
members of the extended NPD kindred (Greer et al.
1997). Samples from 7 patients and from 22 obligate
carriers were analyzed for mutations in the NPC1 gene.
Fifty unrelated, unaffected individuals were used to con-
firm that mutations detected in NPD patients were not
present in the general population.
Mutation Analysis
From the NPC1 cDNA sequence reported by Carstea
et. al. (1997), PCR primers were selected to generate
three overlapping amplicons that span the entire coding
region of the gene; these include a 2.8-kb segment from
C30 to G2835 (F1, 5
′-CGG GGT GCT GAA ACA G; and
R1, 5′-CCC CTT GGA AGA AGT GTA GT), a 1.1-kb
segment from G2811 to C3909 (F2, 5
′-GCACGACTACAC
TTC TTC CA; and R2, 5′-GGC ACA ACT TTT GGC
TTT A), and a 400-bp segment from G3829 to A4224 (F3,
5′-GGA GCC ACT CAC GGA TTA; and R3, 5′-TCC
TGC TTG CCA AAG AAT). By means of standard re-
verse-transcriptase–PCR (RT-PCR) techniques (Mauer
et al. 1990), amplicons were generated from RNA iso-
lated from two patients and from an unaffected relative
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Figure 1 NPD mutation site. The positions of PCR primers F4
(5′-CGG AAG GCA AAC AGA GG), R4 (5′-TTT CTT CAG AGC
GTC AAT AAA G), and R5 (5′-CAC CAA AGG ACC AGG ACA)
are indicated. Primers F4 and R5 generate a 223-bp amplicon that
spans the mutation site (cDNA nucleotide 3097) and the intron/exon
boundary following cDNA nucleotide 3164. The seven-base Bsu36I
restriction-endonuclease recognition sequence present in the wild-type
allele and eliminated by the GrT trinucleotide substitution in NPD
patients is shown. Blackened boxes denote exons; and intronic se-
quences are represented by the thin line.
Figure 2 Analysis of the NPD mutation from genomic DNA.
PCR amplicons generated by use of primers F4 and R5 were digested
with restriction endonuclease Bsu36I and were separated by PAGE.
NPDmutant alleles produce undigested 223-bp amplicons, andnormal
alleles are digested to a smaller, 203-bp fragment. Results of analysis
of an obligate NPD heterozygote (lane 1), an unaffected relative who
is not a carrier (lane 2), patient 3114 (lane 3), the mother of patient
3114 (lane 4), four NPD patients (lanes 5–8), and an NPC patient
(lane 9) are shown.
who was not a carrier. Each amplicon was cloned and
sequenced by means of the Pharmacia T7 Sequencing
Kit (Pharmacia Biotech).
Detection of the NPD Mutation from Genomic DNA
Primers F4 and R4, flanking the NPD mutation site,
were used to amplify the intervening genomic DNA. In
order to select a reverse primer from within the closest
3′ intron that could be used to synthesize, for mutation
analysis, a smaller amplicon directly from genomic
DNA, the forward primer F4 was used to sequence into
the intron, with the genomic PCR product being used
as a template. The intronic sequence was used to design
the reverse primer R5. For mutation analysis, primers
F4 and R5 were used to generate small genomic ampli-
cons that were subjected to restriction-endonuclease di-
gestion to confirm presence or absence of the NPD mu-
tation (see the Results section).
Results
To test the possibility that the gene recently isolated
by Carstea et al. (1997) is also responsible for NPD
disease, NPC1 cDNA from NPD patients was cloned
and sequenced. A single point mutation, a G3097rT trans-
version that converts glycine992 to tryptophan, was found
in eight clones from two patients and was not observed
in cDNAs derived from an unaffected individual. This
single base change abolishes a Bsu36I restriction-enzyme
recognition site.
PCR primers F4 and R4 (fig. 1), which flank the NPD
mutation and generate a 220-bp amplicon from cDNA,
produced a much larger amplicon, ∼1.5 kb, from ge-
nomic DNA. This indicated the presence of intronic
DNA. To generate a small genomic fragment containing
the NPD mutation, forward primer F4 was used to se-
quence through the mutation into the intron. Intronic
sequence data were used to generate reverse primer R5
(fig. 1). Primers F4 and R5, which flank the NPD mu-
tation, amplified, from genomic DNA, a 223-bp segment
that was used, in conjunction with Bsu36I, to screen the
remaining 5 patients and 22 obligate carriers (represen-
tative data are shown in fig. 2).
With the exception of patient 3114, the affected in-
dividuals were homozygous for the mutation. All obli-
gate carriers, with the exception of the mother of patient
3114, were heterozygous for the mutation. None of the
50 unaffected, unrelated individuals had this mutation.
The conclusion that patient 3114 is a compound het-
erozygote is not surprising, because the ancestry of her
mother could not be traced into the NPD kindred.
Discussion
NPD disease has been a major health concern for this
rural community of Nova Scotia for many years. Despite
efforts, both at Dalhousie University (Byers et al. 1989;
Sidhu et al. 1993) and elsewhere (Pentchev et al. 1985,
1986, 1995), to study the biochemistry of NP type II
disease, the underlying defect remains unknown, and
there is little to offer in the way of treatment or cure.
Our previous studies, using classic linkage analysis, have
defined the NPD critical region to a 13-cM chromosomal
segment, between D18S40 and D18S66 (Greer et al.
1997), that contains the NPC1 gene (Carstea et al.
1997). The data reported here show that all of the NPD
patients are homozygous for a mutation in this gene and
that one compound heterozygote is heterozygous for the
NPD mutation. This confirms that NPD and the major
complementation group of NPC are allelic variants of
the same gene, NPC1. Thus, the genetic symbol for the
NPD mutation would be “NPC1, GLY992TRP.”
The common ancestry of NPD provides the oppor-
tunity to develop a rapid and cost-effective PCR-based
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carrier screen for families from Nova Scotia who are at
high risk of having affected children. The identification
of a compound-heterozygote patient warns that, al-
though this analysis detects the commonNPDmutation,
it does not identify all NPC1 alleles that may be seg-
regating in the Nova Scotia families.
Although the function of the NPC1 protein is un-
known, the predicted amino acid sequence suggests that
it is an integral membrane protein containingx13 trans-
membrane regions and a putative sterol-sensing domain
(Carstea et al. 1997). Carstea et al. (1997) have identified
eight distinct NPC1 mutations; these include two frame-
shift mutations that would produce truncated proteins,
a 6-bp deletion (amino acids 200–201), and fivemissense
mutations (located either within or between the trans-
membrane domains). The NPD mutation reported here
(GLY992TRP) is novel, although it is found within the
same interval, between transmembrane domains, that
contains one of the reported NPC1 missense mutations
(GLY928PRO) (Carstea et al. 1997). The NPDmutation
produces a nonconservative amino acid change in a gly-
cine residue that is conserved in both the mouse and
yeast homologues of the Npc1 protein (Loftus et al.
1997). The less severe biochemical defect observed for
NPD cells, relative to most NPC1 mutant cells (Byers et
al. 1989; Sidhu et al. 1993), suggests that the protein
encoded by the NPD mutant allele may retain partial
function, a finding that may have relevance for the de-
velopment of therapeutic approaches to treat the disease.
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